Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sara de la Fuente

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Plos One|December 5, 2019
Drug-related and psychopathological symptoms in HIV-positive men who have sex with men who inject drugs during sex (slamsex): Data from the U-SEX GESIDA 9416 StudyHelen Dolengevich-Segal, Alicia Gonzalez-Baeza, Jorge Valencia, et al.
International Journal of Antimicrobial Agents|April 29, 2026
Safety and tolerability of switching to bictegravir/emtricitabine/tenofovir alafenamide versus continuing dolutegravir/lamivudine in people living with HIV with neuropsychiatric comorbidities: week 24 and 48 results from the Management of INSTI-associated Neuropsychiatric Disorders (MIND) clinical trialIgnacio Perez-Valero, Diana Corona Mata, María Jose Crussells Canales, et al.
Journal of Clinical Medicine|December 9, 2023
Patterns of Sexualized Drug Use among Gay, Bisexual, and Other Men Who Have Sex with Men Living with HIV: Insights from a Comprehensive Study-The U-SEX-2 GESIDA 9416 StudyPablo Ryan, Helen Dolengevich-Segal, Luis Ramos-Ruperto, et al.
Biomedicines|November 27, 2021
Different HCV Exposure Drives Specific miRNA Profile in PBMCs of HIV PatientsDaniel Valle-Millares, Óscar Brochado-Kith, Luz Martín-Carbonero, et al.
The Lancet. HIV|June 9, 2025
Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trialPablo Ryan, José L Blanco, Mar Masia, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
BiomarkersMiquel Massons, Jordi Sarto, Núria Guillén, et al.
HIV Medicine|January 25, 2026
Long-acting cabotegravir and rilpivirine in people with HIV and obesity: Real-world outcomes from the RELATIVITY cohortJesús Troya, Rafael Mican, María José Galindo, et al.
Journal of the International AIDS Society|April 21, 2026
Effectiveness and Persistence of Long-Acting Injectable Cabotegravir and Rilpivirine in Migrant Individuals Living With HIV in Spain: Substudy of the RELATIVITY CohortJara Llenas-García, María Del Mar Arcos Rueda, Ruth Calderón Hernaiz, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Plos One|December 5, 2019
Drug-related and psychopathological symptoms in HIV-positive men who have sex with men who inject drugs during sex (slamsex): Data from the U-SEX GESIDA 9416 StudyHelen Dolengevich-Segal, Alicia Gonzalez-Baeza, Jorge Valencia, et al.
International Journal of Antimicrobial Agents|April 29, 2026
Safety and tolerability of switching to bictegravir/emtricitabine/tenofovir alafenamide versus continuing dolutegravir/lamivudine in people living with HIV with neuropsychiatric comorbidities: week 24 and 48 results from the Management of INSTI-associated Neuropsychiatric Disorders (MIND) clinical trialIgnacio Perez-Valero, Diana Corona Mata, María Jose Crussells Canales, et al.
Journal of Clinical Medicine|December 9, 2023
Patterns of Sexualized Drug Use among Gay, Bisexual, and Other Men Who Have Sex with Men Living with HIV: Insights from a Comprehensive Study-The U-SEX-2 GESIDA 9416 StudyPablo Ryan, Helen Dolengevich-Segal, Luis Ramos-Ruperto, et al.
Biomedicines|November 27, 2021
Different HCV Exposure Drives Specific miRNA Profile in PBMCs of HIV PatientsDaniel Valle-Millares, Óscar Brochado-Kith, Luz Martín-Carbonero, et al.
The Lancet. HIV|June 9, 2025
Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trialPablo Ryan, José L Blanco, Mar Masia, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
BiomarkersMiquel Massons, Jordi Sarto, Núria Guillén, et al.
HIV Medicine|January 25, 2026
Long-acting cabotegravir and rilpivirine in people with HIV and obesity: Real-world outcomes from the RELATIVITY cohortJesús Troya, Rafael Mican, María José Galindo, et al.
Journal of the International AIDS Society|April 21, 2026
Effectiveness and Persistence of Long-Acting Injectable Cabotegravir and Rilpivirine in Migrant Individuals Living With HIV in Spain: Substudy of the RELATIVITY CohortJara Llenas-García, María Del Mar Arcos Rueda, Ruth Calderón Hernaiz, et al.
Pageof 3